AndreaBozzo/ceres-open-data-index huggingface dataset:
2010 State Profile — Mississippi

This state profile includes data from facilities in Mississippi that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Mississippi. In Mississippi, 102 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 5,037 clients in substance abuse treatment on March 31, 2010. The survey response rate in Mississippi was 96.3%.
Organisational development in general practice: lessons from practice and professional development plans (PPDPs)

Background
          Improving the quality and effectiveness of clinical practice is becoming a key task within all health services. Primary medical care, as organised in the UK is composed of clinicians who work in independent partnerships (general practices) that collaborate with other health care professionals. Although many practices have successfully introduced innovations, there are no organisational development structures in place that support the evolution of primary medical care towards integrated care processes. Providing incentives for attendance at passive educational events and promoting 'teamwork' without first identifying organisational priorities are interventions that have proved to be ineffective at changing clinical processes. A practice and professional development plan feasibility study was evaluated in Wales and provided the experiential basis for a summary of the lessons learnt on how best to guide organisational development systems for primary medical care.
        
        
          Results
          Practice and professional development plans are hybrids produced by the combination of ideas from management (the applied behavioural science of organisational development) and education (self-directed adult learning theories) and, in conceptual terms, address the lack of effectiveness of passive educational strategies by making interventions relevant to identified system wide needs. In the intervention, each practice participated in a series of multidisciplinary workshops (minimum 4) where the process outcome was the production of a practice development plan and a set of personal portfolios, and the final outcome was a realised organisational change.
          It was apparent during the project that organisational admission to a process of developmental planning needed to be a stepwise process, where initial interest can lead to a fuller understanding, which subsequently develops into motivation and ownership, sufficient to complete the exercise. The advantages of introducing expert external facilitation were clear: evaluations of internal group processes were possible, strategic issues could be raised and explored and financial probity ensured. These areas are much more difficult to examine when only internal stakeholders are engaged in a planning process.
        
        
          Conclusions
          It is not possible to introduce practice and professional development plans (organisational development and organisational learning projects) in a publicly funded health care system without first addressing existing educational and management structures. Existing systems are based on educational credits for attendance and emerging accountability frameworks (criteria checklists) for clinical governance. Moving to systems that are less summative and more formative, and based on the philosophies of continual quality improvement, require changes to be made in the relevant support systems in order achieve policy proposals.
Compound 529386: 1-Prop-1-enylsulfonylsulfanylpropane

Chemical compound data from PubChem database. IUPAC Name: 1-prop-1-enylsulfonylsulfanylpropane. Molecular Formula: C6H12O2S2. Molecular Weight: 180.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525794: N-(3-Methylphenyl)-N'-(3-bromophenyl)formamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(3-bromophenyl)-N-(3-methylphenyl)methanimidamide. Molecular Formula: C14H13BrN2. Molecular Weight: 289.17. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Library LinkOut

LinkOut is a service that allows you to link directly from PubMed and other NCBI databases to a wide range of information and services beyond the NCBI systems. LinkOut aims to facilitate access to relevant online resources in order to extend, clarify, and supplement information found in NCBI databases.

Third parties can link directly from PubMed and other Entrez database records to relevant Web-accessible resources beyond the Entrez system. Includes full-text publications, biological databases, consumer health information and research tools.
Compound 529277: 3,4-Dimethyl-1-pentyne

Chemical compound data from PubChem database. IUPAC Name: 3,4-dimethylpent-1-yne. Molecular Formula: C7H12. Molecular Weight: 96.17. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2021-2022 NSDUH: Model-Based Estimated Prevalence for States

Browse state-level percentage estimates based on the 2021-2022 National Surveys on Drug Use and Health (NSDUH). The 37 tables include estimates for 35 measures of substance use and mental health, by age group, along with 95% confidence intervals. The percentages are based on small area estimation (SAE) methods, in which state-level NSDUH data are combined with other data from smaller geographies. The combined data are used to create modeled state estimates of the civilian, noninstitutionalized population ages 12 and older, or adults 18 and older for mental health measures. Each table covers a single measure by state, region, and age group.The indicators are presented in the following 37 tables:Drug use and Perceived RiskIllicit Drug Use in the Past MonthMarijuana Use in the Past YearMarijuana Use in the Past MonthPerceptions of Great Risk from Smoking Marijuana Once a MonthFirst Use of Marijuana in the Past Year (among those at risk for initiation)Illicit Drug Use Other than Marijuana in the Past MonthCocaine Use in the Past YearPerceptions of Great Risk from using Cocaine Once a MonthHeroin Use in the Past YearPerceptions of Great Risk from Trying Heroin Once or TwiceHallucinogen Use in the Past YearMethamphetamine Use in the Past YearPrescription Pain Reliever Misuse in the Past YearOpioid Misuse in the Past YearAlcoholAlcohol Use in the Past MonthBinge Alcohol Use in the Past MonthPerceptions of Great Risk from Having Five or More Drinks of an Alcoholic Beverage Once or Twice a WeekAlcohol Use, Binge Alcohol Use in the Past Month, and Perceptions of Great Risk from Having Five or More Drinks of an Alcoholic Beverage Once or Twice a Week (among people aged 12 to 20)TobaccoTobacco Product Use in the Past MonthCigarette Use in the Past MonthPerceptions of Great Risk from Smoking One or More Packs of Cigarettes per DaySubstance Use DisordersSubstance Use Disorder in the Past YearAlcohol Use Disorder in the Past YearAlcohol Use Disorder in the Past Year (among people aged 12 to 20)Drug Use Disorder in the Past YearPain Reliever Use Disorder in the Past YearOpioid Use Disorder in the Past YearSubstance Use TreatmentReceived Substance Use Treatment in the Past YearClassified as Needing Substance Use Treatment in the Past YearDid Not Receive Substance Use Treatment in the Past Year among those Classified as Needing Substance Use TreatmentMental IllnessAny Mental Illness in the Past YearSerious Mental Illness in the Past YearReceived Mental Health Treatment in the Past YearMajor Depressive Episode in the Past YearSuicidalityHad Serious Thoughts of Suicide in the Past YearMade Any Suicide Plans in the Past YearAttempted Suicide in the Past YearThe tables are available in an Excel spreadsheet, a PDF file, or as a zip file of 37 CSV text files.
Compound 525866: N,N-Dimethyl-2-phenyl-N'-octyl-acetamidine

Chemical compound data from PubChem database. IUPAC Name: N,N-dimethyl-N'-octyl-2-phenylethanimidamide. Molecular Formula: C18H30N2. Molecular Weight: 274.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The vitamin D receptor polymorphism in the translation initiation codon is a risk factor for insulin resistance in glucose tolerant Caucasians

Background
          Although vitamin D receptor (VDR) polymorphisms have been shown to be associated with abnormal glucose metabolism, the reported polymorphisms are unlikely to have any biological consequences. The VDR gene has two potential translation initiation sites. A T-to-C polymorphism has been noted in the first ATG (f allele), abolishing the first translation initiation site and resulting in a peptide lacking the first three amino acids (F allele). We examined the role of this polymorphism in insulin sensitivity and beta cell function. This study included 49 healthy Caucasian subjects (28 females, age 28 ± 1 years old, body mass index 24.57 ± 0.57 kg/m2, waist-hip ratio 0.81 ± 0.01 cm/cm). They were all normotensive (less than 140/90 mmHg) and glucose tolerant, which was determined by a standard 75-gm oral glucose tolerance test. Their beta cell function (%B) and insulin sensitivity (%S) were calculated based on the Homeostasis Model Assessment (HOMA). Their genotypes were determined by a polymerase chain reaction-restriction fragment length polymorphism analysis. Phenotypes were compared between genotypic groups.
        
        
          Results
          There were 18 FF, 21 Ff, and 10 ff subjects. Since only 10 ff subjects were identified, they were pooled with the Ff subjects during analyses. The FF and Ff/ff groups had similar glucose levels at each time point before and after a glucose challenge. The Ff/ff group had higher insulin levels than the FF group at fasting (P=0.006), 30 minutes (P=0.009), 60 minutes (P=0.049), and 90 minutes (P=0.042). Furthermore, the Ff/ff group also had a larger insulin area under the curve than the FF group (P=0.009). While no difference was noted in %B, the Ff/ff group had a lower %S than the FF group (0.53 vs. 0.78, P=0.006). A stepwise regression analysis confirmed that the Fok I polymorphism was an independent determinant for %S, accounting for 29.3% of variation in %S when combined with waist-hip ratio.
        
        
          Conclusions
          We report that the Fok I polymorphism at the VDR gene locus is associated with insulin sensitivity, but has no influence on beta cell function in healthy Caucasians. Although this polymorphism has been shown to affect the activation of vitamin D-dependent transcription, the molecular basis of the association between this polymorphism and insulin resistance remains to be determined.
2013 CMHS Uniform Reporting System (URS) Table for Rhode Island

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for Rhode Island for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program.  State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
COVID-19 State Profile Report - Alaska

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Patent AT-E399739-T1: [Translated] MICROMECHANICAL SENSOR

A micromechanical sensor and a method for manufacturing same are described. A secure diaphragm restraint, independent of fluctuations in the cavern etching process due to the process technology, and a free design of the diaphragm are made possible by designing a suitable connection of the diaphragm in an oxide layer created by local oxidation. The micromechanical sensor includes, for example, a substrate, an external oxide layer formed in a laterally external area in the substrate, a diaphragm having multiple perforation holes formed in a laterally internal diaphragm area, a cavern etched in the substrate beneath the diaphragm, whereby the diaphragm is suspended in a suspension area of the external oxide layer which tapers toward connecting points of the diaphragm and the diaphragm is situated in its vertical height between a top side and a bottom side of the external oxide layer.
Compound 525591: N,N-Dimethyl-N'-(4-chlorophenyl)-p-chlorobenzamidine

Chemical compound data from PubChem database. IUPAC Name: 4-chloro-N'-(4-chlorophenyl)-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C15H14Cl2N2. Molecular Weight: 293.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - Table II. Babesiosis to Campylobacteriosis

NNDSS - Table II. Babesiosis to Campylobacteriosis - 2018. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states or territory.

Note:

This table contains provisional cases of selected national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up.  Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html 

Footnotes:

 C.N.M.I.: Commonwealth of Northern Mariana Islands. 
U: Unavailable. —: No reported cases. N: Not reportable. NA:  Not Available.  NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

* Case counts for reporting years 2017 and 2018 are provisional and subject to change. Data for years 2013 through 2016 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf.
Vaccination Coverage among Pregnant Women

Vaccination Coverage among Pregnant Women

• Data on influenza and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination coverage at the state level from the Pregnancy Risk Assessment Monitoring System (PRAMS) for women who had a recent live birth by age and race/ethnicity.

• Additional information available at https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/index.html and https://www.cdc.gov/flu/fluvaxview/index.htm
Digital analysis of cDNA abundance; expression profiling by means of restriction fragment fingerprinting

Background
          Gene expression profiling among different tissues is of paramount interest in various areas of biomedical research. We have developed a novel method (DADA, Digital Analysis of cDNA Abundance), that calculates the relative abundance of genes in cDNA libraries.
        
        
          Results
          DADA is based upon multiple restriction fragment length analysis of pools of clones from cDNA libraries and the identification of gene-specific restriction fingerprints in the resulting complex fragment mixtures. A specific cDNA cloning vector had to be constructed that governed missing or incomplete cDNA inserts which would generate misleading fingerprints in standard cloning vectors. Double stranded cDNA was synthesized using an anchored oligo dT primer, uni-directionally inserted into the DADA vector and cDNA libraries were constructed in E. coli. The cDNA fingerprints were generated in a PCR-free procedure that allows for parallel plasmid preparation, labeling, restriction digest and fragment separation of pools of 96 colonies each. This multiplexing significantly enhanced the throughput in comparison to sequence-based methods (e.g. EST approach). The data of the fragment mixtures were integrated into a relational database system and queried with fingerprints experimentally produced by analyzing single colonies. Due to limited predictability of the position of DNA fragments on the polyacrylamid gels of a given size, fingerprints derived solely from cDNA sequences were not accurate enough to be used for the analysis. We applied DADA to the analysis of gene expression profiles in a model for impaired wound healing (treatment of mice with dexamethasone).
        
        
          Conclusions
          The method proved to be capable of identifying pharmacologically relevant target genes that had not been identified by other standard methods routinely used to find differentially expressed genes. Due to the above mentioned limited predictability of the fingerprints, the method was yet tested only with a limited number of experimentally determined fingerprints and was able to detect differences in gene expression of transcripts representing 0.05% of the total mRNA population (e.g. medium abundant gene transcripts).
Compound 529824: [10,13-dimethyl-17-(5-propan-2-ylhept-5-en-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate

Chemical compound data from PubChem database. IUPAC Name: [10,13-dimethyl-17-(5-propan-2-ylhept-5-en-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate. Molecular Formula: C31H50O2. Molecular Weight: 454.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2010-2011 NSDUH State Prevalence Estimates – Excel Tables

This page presents the table of contents of excel tables of State estimates for measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Results are provided by age group.
Patent AT-E400332-T1: [Translated] SNOW SLIDING BOARD

The board has orientation-adjustable bindings each having a center (16, 17) defined as a rotation point of an orientation adjustment mechanism of the respective binding. The centers (16, 17) are separated by a distance (S) comprised between 45 and 55cms. A length of the board is defined by a distance separating front and rear end points (2, 3). A width of the board is defined by a distance separating points (7, 8) of sidecuts (9) arranged on a straight line (10) perpendicular to a median longitudinal axis (4) connecting the points (2, 3). The length to width ratio is lesser than 4.85.
2012 NSDUH Mental Health Surveillance Study Design and Estimation Report

This report describes the design and estimation procedures to the supplemental Mental Health Surveillance Study (MHSS) data collection to the 2012 National Survey on Drug Use and Health (NSDUH). The report describes instruments used in measuring mental illness, sample design and selection (including the MHSS clinical sample characteristics), data collection and processing, weighting, nonresponse adjustment, and the development of the model for estimating mental illness.
Compound 529279: 2-Hexyne, 4,4-dimethyl

Chemical compound data from PubChem database. IUPAC Name: 4,4-dimethylhex-2-yne. Molecular Formula: C8H14. Molecular Weight: 110.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529810: 3-Buten-2-one, 2,4,6-trichlorophenyl hydrazone

Chemical compound data from PubChem database. IUPAC Name: N-(but-3-en-2-ylideneamino)-2,4,6-trichloroaniline. Molecular Formula: C10H9Cl3N2. Molecular Weight: 263.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
America's Need for and Receipt of Substance Use Treatment in 2015

This report uses 2015 National Survey on Drug Use and Health (NSDUH) data to examine the need for and receipt of substance use treatment at a specialty facility among people aged 12 or older. This report also examines perceived need for substance use treatment. Comparisons are made between adolescents aged 12 to 17, young adults aged 18 to 25, and adults aged 26 or older.
Compound 528872: Ephedrine, N-TFA-O-TMS

Chemical compound data from PubChem database. IUPAC Name: 2,2,2-trifluoro-N-methyl-N-(1-phenyl-1-trimethylsilyloxypropan-2-yl)acetamide. Molecular Formula: C15H22F3NO2Si. Molecular Weight: 333.42. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.